Aficamten Reduced LVOT Gradients and Improved NYHA Class and NT-proBNP in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Disopyramide.
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction Results Will Be Presented in Late Breaking Clinical Trial Session at the American. | February 15, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
Cytokinetics, IncorporatedDecember 14, 2020 GMT
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data relating to the impact of patient characteristics on treatment effect in FORTITUDE-ALS, the Phase 2 clinical trial of
reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), were presented at the 31st International Symposium on ALS/MND. Additionally, the company announced that the design of COURAGE-ALS (Clinical Outcomes Using
R
eldesemtiv on ALSFRS-R in a Global Evaluation in ALS), a planned Phase 3 clinical trial of